Biosimilars in rheumatology and other fields of medicine

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2014, Vol 68, Issue

Abstract

Biosimilars are follow-up versions of innovative medicines with proved high similarity to the reference product. There may be some minor differences in clinically inactive components of a molecule which can be clinically significant, but they do not substantially affect the high resemblance to the original drug in their safety and potency.Introduction of the biosimilars brings hope to reduce the cost of treatment, so their availability will increase further as the expiration of patents on biotechnologically produced drugs will follow, which is currently taking place. There are new biosimilar drugs being introduced recently; these are monoclonal antibodies. They are much more structurally complicated compared to the first biotech drugs such as insulin, and their production processes are much more complex. Biosimilars as the end products of such sophisticated technology are affected by many variables. It is not possible to create “biogenerics,” but only biosimilar drugs. Therefore, despite their similarities to the reference molecules, biosimilars are too different to forego clinical trials. Clinical trials of biosimilars need to be much broader than for generics, but they are limited compared to the reference biologicals’ testing. Placebo controlled clinical trials are not required before registering a new biosimilar. Immunogenicity is a major source of concern related to biosimilars, although there may be the same problem with the original drugs.

Authors and Affiliations

Marcin Milchert, Jacek Fliciński, Marek Brzosko

Keywords

Related Articles

Efektywność i bezpieczeństwo preparatów probiotycznych stosowanych w terapii nieswoistych zapaleń jelit

Inflammatory bowel disease (IBD) is characterized by an aggressive immune response to luminal antigens including those of commensal microbiota, which are essential for intestinal homeostasis and appear to play a role in...

Nowotworowe komórki macierzyste

Teoria istnienia nowotworowych komórek macierzystych (cancer stem cells – CSC) zyskuje coraz większe znaczenie w świecie medycyny. Liczne dowody badań in vivo oraz in vitro wskazują, że to właśnie populacja niezróżnicowa...

Proteazy serynowe i ich funkcja w patogenezie zakażeń bakteryjnych

Nadużywanie antybiotyków w medycynie, weterynarii, hodowli zwierząt, rolnictwie, kosmetologii czy w przemyśle, przyczyniło się do rozprzestrzenienia zjawiska oporności wśród wielu gatunków drobnoustrojów. Poszukiwanie al...

Sprzężone dieny kwasu linolowego jako potencjalny czynnik prewencyjny w profilaktyce nowotworów piersi

Nowotwory złośliwe są drugą z najczęstszych przyczyn zgonów w Polsce, zarówno wśród kobiet, jak i wśród mężczyzn, a rak piersi zajmuje wśród nich pierwsze miejsce spośród zachorowań diagnozowanych u kobiet. W 2008 r. roz...

The problem of vaginismus with congenital malformation of the genital tract

The persistent or recurrent difficulties of the woman to allow vaginal entry of a penis, a finger, and/or any object, despite the woman’s expressed wish to do so” is vaginismus. Early traumatic sexual experiences (e.g. s...

Download PDF file
  • EP ID EP67445
  • DOI -
  • Views 148
  • Downloads 0

How To Cite

Marcin Milchert, Jacek Fliciński, Marek Brzosko (2014). Biosimilars in rheumatology and other fields of medicine. Advances in Hygiene and Experimental Medicine, 68(), 970-975. https://europub.co.uk/articles/-A-67445